Fig. 2

Combining clinical targetable mutations and PScore distinguishes the survival of BRAF-mutated melanoma patients. A Heatmap showing different mutation statuses and corresponding PScore groups of metastatic patients in the TCGA-SKCM cohort. The top 10 high-frequency mutations, common therapeutic targets, and PRGs with frequencies greater than 10% are displayed. Mutation marked with “***” on the left indicates significant differences in PScore. B Chi-square test for different PScore groups and BRAF mutations. The x-axis represents the PScore group, the y-axis represents the proportion of patients, and different colors in the bar graph represent BRAF mutation status. C Comparison of PScore between BRAF-mutated and non-BRAF-mutated groups in all metastatic melanoma. The x-axis represents BRAF mutation status, and the y-axis represents PScore. D Survival analysis based on whether BRAF is mutated in metastatic melanoma patients. The x-axis represents survival time (unit: year), the y-axis represents OS rate. E Survival analysis based on BRAF mutation and PScore groups in metastatic melanoma patients